Skip to search.
 Dow Down 0.60% Nasdaq Down 0.07%

Cubist Pharmaceuticals Inc. (CBST)

-NasdaqGS

39.87 Down 0.04(0.10%) May 25, 4:00PM EDT|After Hours: 39.87 0.00 (0.00%) May 25, 4:48PM EDT

ProfileGet Profile for:
Cubist Pharmaceuticals Inc.
65 Hayden Avenue
Lexington, MA 02421
United States - Map
Phone: 781-860-8660
Fax: 781-240-0256
Website: http://www.cubist.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:669

Business Summary 

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), a once-daily, bactericidal, and intravenous antibiotic with activity against gram-positive organisms, including methicillin-resistant staphylococcus aureus; and ENTEREG, an alvimopan for acceleration of upper and lower gastrointestinal recovery. It also co-promotes DIFICIDTM used for the treatment of clostridium difficile-associated diarrhea in the United States. The company’s clinical development product pipeline consists of CXA-201, which is in the Phase III clinical trial for patients with complicated urinary tract infections and complicated intra-abdominal infections. It is also developing CXA-201 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. In addition, the company’s products under development comprise CB-315, an oral, bactericidal lipopeptide with in vitro bactericidal activity against C. difficile, for the treatment of clostridium difficile-associated diarrhea (CDAD); and CB-5945, an oral, peripherally-restricted mu opioid receptor antagonist for the treatment of chronic OIC, as well as CB-625 for acute pain. Further, its pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. The company also has collaborations and agreements with third parties that are focused on the research and development of acute care products. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Cubist Pharmaceuticals Inc.

Corporate Governance 
Cubist Pharmaceuticals Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (Low Concern), Shareholder Rights (High Concern).
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Michael W. Bonney B.A., 53
Chief Exec. Officer, Pres and Director
1.42M504.00K
Mr. David W. J. McGirr MBA, 57
Chief Financial Officer, Principal Accounting Officer and Sr. VP
742.00K1.20M
Mr. Robert J. Perez MBA , 47
Chief Operating Officer and Exec. VP
878.00K655.00K
Dr. Steven C. Gilman Ph.D., 59
Chief Scientific Officer and Exec. VP of R&D
796.00K1.49M
Ms. Tamara L. Joseph J.D., 49
Sr. VP, Sec. and Gen. Counsel
791.00K0.00
Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders